PD-L1 IHC 22C3 pharmDx can help identify cervical cancer patients for treatment with KEYTRUDA
PD-L1 is a proven biomarker for patient response to KEYTRUDA in cervical cancer
Cervical cancer is the third most common gynecologic cancer in the United States
Patients with metastatic cervical cancer have poor prognosis—the median overall survival is only one year, with short-lived responses to treatment and rapid deterioration of quality of life
Anti-PD-1 therapies are a promising new treatment class for many cancer types—the KEYNOTE-158 clinical trial studied the efficacy of KEYTRUDA, an anti-PD-1 monotherapy, in patients with recurrent or metastatic cervical cancer
IHC testing for PD-L1 expression levels enables identification of patients most likely to benefit from anti-PD-1 monotherapy
Trust the ONE PD-L1 test FDA-approved to determine PD-L1 expression in patients with cervical cancer
Proven in KEYNOTE-158 for PD-L1 results in cervical cancer that you can rely on
PD-L1 IHC 22C3 pharmDx was the only IHC assay used to assess patients for PD-L1 expression in the KEYNOTE-158 trial
* Prevalence calculation based on patients with known PD-L1 expression (Cohort E, n=97)—1 patient (1% of the cohort) had unknown PD-L1 expression status; † Efficacy results based on patients in KEYNOTE-158 Cohort E with tumors that expressed PD-L1 with a CPS ≥ 1 and who received at least one line of chemotherapy in the metastatic setting (n=77)
PD-L1 IHC 22C3 pharmDx Cervical Cancer Interpretation Training ProgramGet the training that may help you accurately evaluate and score PD-L1 expression in patients with cervical cancer
PD-L1 IHC 22C3 pharmDx Cervical Cancer Interpretation ManualRefer to the Cervical Cancer Interpretation Manual to review validated scoring guidelines that can help identify patients for treatment with KEYTRUDA
PD-L1 testing with PD-L1 IHC 22C3 pharmDx should be an integral part of patient care from day ONE
Because durations of response are short at first line and there is no standard of care at second line, it is critical to assess PD-L1 expression status upon diagnosis
Platinum-based chemotherapy regimens are the most common first-line treatment for metastatic cervical cancer
However, treatment efficacy is variable, with patients experiencing progression-free survival (PFS) of less than one year
Additionally, following first-line treatment, there is no universally accepted standard of care, and PFS is even shorter, typically less than six months
KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
References:1. PD-L1 IHC 22C3 pharmDx [package insert]. Carpinteria, CA: Dako, Agilent Pathology Solutions; 2018. 2. Keytruda [package insert]. Kenilworth, NJ: Merck & Co., Inc.; 2018. 3. Reddy OL, Shintaku PI, Moatamed NA. Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas. Diagn Pathol. 2017;12(1):45. 4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-30. 5. Borcoman E, Tourneau CL. Pembrolizumab in cervical cancer: latest evidence and clinical usefulness. Ther Adv Med Oncol. 2017;9(6):431-439. 6. Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N, for ESMO Guidelines Committee. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv72-iv83. 7. Boussios S, Seraj E, Zarkavelis G, et al. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review. Crit Rev Oncol Hematol. 2016;108:164-174.
For countries outside of the United States, see the local KEYTRUDA product label for approved indications and expression cutoff values to guide therapy.